PL2985032T3 - Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona - Google Patents

Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona

Info

Publication number
PL2985032T3
PL2985032T3 PL15171991T PL15171991T PL2985032T3 PL 2985032 T3 PL2985032 T3 PL 2985032T3 PL 15171991 T PL15171991 T PL 15171991T PL 15171991 T PL15171991 T PL 15171991T PL 2985032 T3 PL2985032 T3 PL 2985032T3
Authority
PL
Poland
Prior art keywords
disease
glyx
huntington
parkinson
alzheimer
Prior art date
Application number
PL15171991T
Other languages
English (en)
Inventor
Joseph Moskal
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of PL2985032T3 publication Critical patent/PL2985032T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Ceramic Products (AREA)
  • Glass Compositions (AREA)
  • Compositions Of Oxide Ceramics (AREA)
PL15171991T 2009-10-05 2010-10-05 Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona PL2985032T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24865009P 2009-10-05 2009-10-05
PCT/US2010/051415 WO2011044089A2 (en) 2009-10-05 2010-10-05 Methods of treating depression and other related diseases
EP14169137.8A EP2813236A1 (en) 2009-10-05 2010-10-05 GLYX for use in the treatment of depression or anxiety
EP10822514.5A EP2485751B1 (en) 2009-10-05 2010-10-05 GLYX-13 for use in a method of treating refractory depression
EP15171991.1A EP2985032B1 (en) 2009-10-05 2010-10-05 Glyx for use in the treatment of alzheimer's disease, parkinson's disease or huntington's disease

Publications (1)

Publication Number Publication Date
PL2985032T3 true PL2985032T3 (pl) 2019-07-31

Family

ID=43857351

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10822514T PL2485751T3 (pl) 2009-10-05 2010-10-05 GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie
PL15171991T PL2985032T3 (pl) 2009-10-05 2010-10-05 Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10822514T PL2485751T3 (pl) 2009-10-05 2010-10-05 GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie

Country Status (12)

Country Link
EP (4) EP2485751B1 (pl)
CY (1) CY1118530T1 (pl)
DK (2) DK2985032T3 (pl)
ES (2) ES2721448T3 (pl)
HR (1) HRP20140784T1 (pl)
HU (1) HUE043807T2 (pl)
PL (2) PL2485751T3 (pl)
PT (2) PT2985032T (pl)
RS (1) RS53513B1 (pl)
SI (1) SI2485751T1 (pl)
SM (1) SMT201400117B (pl)
WO (1) WO2011044089A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101769999B1 (ko) 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Ｎｍｄａ 수용체 조절제 및 그의 용도
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CA2789331C (en) 2010-02-11 2017-11-07 Northwestern University Secondary structure stabilized nmda receptor modulators and uses thereof
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
SG194230A1 (en) * 2011-04-27 2013-12-30 Univ Northwestern Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
WO2014059326A2 (en) * 2012-10-12 2014-04-17 Northwestern University Methods of identifying compounds for treating depression and other related diseases
CA2899010A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
PE20151436A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
BR112015018087B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
EP3721799A1 (en) * 2013-12-13 2020-10-14 Northwestern University Methods of treating brain disorders or identifying biomarkers related thereto
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
WO2015200322A1 (en) * 2014-06-23 2015-12-30 Northwestern University Methods of treating or ameliorating migraine
RU2017107033A (ru) * 2014-08-14 2018-09-14 Наурекс, Инк. Способы лечения депрессии с применением модуляторов nmda
CN108601814A (zh) * 2015-10-16 2018-09-28 西北大学 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合
US10591461B2 (en) 2016-04-28 2020-03-17 The Trustees Of The University Of Pennsylvania Method of drug design and optimisation utilizing stereochemical mimicry
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
US10918637B2 (en) 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
AU2017306152A1 (en) 2016-08-01 2019-01-31 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US20030065138A1 (en) * 2001-03-07 2003-04-03 University Of Utah Research Foundation Linear gamma-carboxyglutamate rich conotoxins
WO2002072609A2 (en) * 2001-03-12 2002-09-19 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
CA2534909A1 (en) * 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders

Also Published As

Publication number Publication date
EP2985032A1 (en) 2016-02-17
EP2485751A2 (en) 2012-08-15
EP2985032B1 (en) 2019-01-02
DK2485751T3 (da) 2014-08-18
WO2011044089A3 (en) 2012-02-16
PT2485751E (pt) 2014-09-01
CY1118530T1 (el) 2017-07-12
HRP20140784T1 (hr) 2014-10-10
EP2813236A1 (en) 2014-12-17
PT2985032T (pt) 2019-04-24
PL2485751T3 (pl) 2014-10-31
EP3488856A1 (en) 2019-05-29
WO2011044089A2 (en) 2011-04-14
EP2485751B1 (en) 2014-05-21
SI2485751T1 (sl) 2014-10-30
RS53513B1 (sr) 2015-02-27
EP2485751A4 (en) 2013-03-13
DK2985032T3 (en) 2019-04-15
ES2493316T3 (es) 2014-09-11
ES2721448T3 (es) 2019-07-31
HUE043807T2 (hu) 2019-09-30
SMT201400117B (it) 2014-11-10

Similar Documents

Publication Publication Date Title
PL2985032T3 (pl) Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona
IL219412A (en) Preparations containing Busimanden for use in the treatment of Alzheimer's or Alzheimer's disease
IL213259A0 (en) Composition for the use to treat alzheimer's disease
ZA201007460B (en) Use of epothelone in treating tau-associated disease including alzheimer's disease
EP2382176A4 (en) USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2485733A4 (en) METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2707369A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
IL205153A0 (en) Compositions for treating parkinson's disease
ZA201201222B (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivatives,methods for the production thereof and use thereof for treating diseases
IL209131A0 (en) Rasagiline for parkinson's disease modification
PL2252300T3 (pl) Zastosowanie 2,4-pirymidynodiamin do leczenia miażdżycy
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
IL213120A0 (en) Method for treating parkinson' s disease
WO2010085799A9 (en) Compositions and method for the treatment of parkinson's disease
EP2421554A4 (en) TISSUE KALLICREIN FOR THE TREATMENT OF HUNTINGTON'S DISEASE
IL217149A0 (en) Compositions and methods for treating parkinson's disease
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
GB201220630D0 (en) Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldtjakob disease or diabetes mellitus
PL2593129T3 (pl) Nonapeptyd pat do stosowania w leczeniu choroby alzheimera
GB0814043D0 (en) The treatment of skin disorders
HK1175364A (en) Methods for treating parkinson's disease
IL214340A0 (en) Methods and compositions for treating alzheimer's disease
GB0811555D0 (en) Treatment of Alzheimer's disease
HK1195902A (en) Compositions and methods for treating alzheimer's disease